Long-acting RNA therapy to control fibrinolysis and reduce bleeding
Official title: Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy
Funded at Versiti Blood Health, INC. · NIH-11380066 · Data updated 2026-11-12
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Blood Health, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $701,131 |
| NIH project number | 5R01HL166382-04 |
| Project ID | NIH-11380066 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with bleeding disorders or acute bleeding who could benefit from longer-lasting antifibrinolytic protection.
✕Less likely to help
Patients unlikely to benefit include those without bleeding disorders or acute bleeding issues, or those with contraindications to RNA therapies or lipid nanoparticle delivery.
What this research studies
This project tests a long-acting RNA drug designed to silence plasminogen, the precursor to plasmin, to reduce excessive clot breakdown. The therapy uses a lipid nanoparticle delivery system to reach patients’ bodies and provide extended anti-bleeding effects. Researchers will develop and test the siPlg approach in relevant models to understand how it changes bleeding outcomes over time. The work focuses on translating a molecular strategy into a treatment that could help people who experience acute bleeding, including traumatic scenarios.
Why it matters
Potential benefit: If successful, the therapy could provide longer-lasting control of bleeding and fewer transfusions for patients with bleeding disorders or acute hemorrhage.
How similar studies have gone: Previous antifibrinolytic approaches work in acute bleeds, but this long-acting RNA strategy is a novel extension aimed at sustained effect.
Where this research is happening
-
Versiti Blood Health, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Kastrup, Christian — Versiti Blood Health, INC.
- Study coordinator: Kastrup, Christian
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
-
Heavy menstrual bleeding treatment for adolescents with bleeding disorders
A multicenter study will compare two progestin-based treatments for heavy periods in teens and young adults with bleeding disorders to see which helps reduce bleeding and improves well-being.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.